Abiopharma

🔍 Gordon Scott (Executive)

Company: Chicago Atlantic BDC, Inc. (LIEN)

Report Date: 2026-08-25

Detailed Transactions and Holdings:

• Acquired 250 shares of Common Stock at $10.12 per share (Direct)
  Date: 2026-08-25 | Code: P | equity_swap_involved: false | shares_owned_after: 88,573.00 | transaction_form_type: 4
• Acquired 2,483 shares of Common Stock at $10.15 per share (Direct)
  Date: 2026-08-26 | Code: P | equity_swap_involved: false | shares_owned_after: 91,056.00 | transaction_form_type: 4
• Acquired 5,000 shares of Common Stock at $10.188 per share (Direct)
  Date: 2026-08-27 | Code: P | equity_swap_involved: false | shares_owned_after: 96,056.00 | transaction_form_type: 4 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-25 | Code: H | nature_of_ownership: Chicago Atlantic BDC Advisers, LLC | shares_owned_after: 2,887,204.00 | Footnotes: F1

Footnotes:

• F1: Scott Gordon directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the shares of Common Stock owned by Chicago Atlantic BDC Advisers, LLC. Mr. Gordon disclaims beneficial ownership of the shares of Common Stock owned by Chicago Atlantic BDC Advisers, LLC except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
• F2: The price reported reflects the weighted-average purchase price from several discrete transactions executed throughout the Transaction Date at prices that ranged from $10.18 to $10.19 per share. Upon request, the Reporting Person has agreed to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each price within the range set forth in this footnote.